Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.52 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.52 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23311429 | 1.00 | CRBN (0.52) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL20987588 | 1.00 | CRBN (0.52) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL14571204 | 1.00 | CRBN (0.52) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL88947 | 0.92 | — | — | |
| SCHEMBL336077 | 0.92 | OR51E2 (0.50) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL14433008 | 0.90 | ALDH1A1 (0.43) | CRBNFKBP5OR51E2KDM4EGAA | |
| Hydrochloric Acid SCHEMBL3838535 | 0.90 | — | — | |
| Azetidine SCHEMBL18173582 | 0.86 | OR51E2 (0.43) | CRBNFKBP5OR51E2GAA | |
| SCHEMBL21499432 | 0.85 | CRBN (0.37) | CRBNFKBP5OR51E2KDM4EGAA | |
| SCHEMBL10522634 | 0.82 | CXCR4 (0.45) | CRBNFKBP5OR51E2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708337-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | G1 THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| CN-108752286-B | 1,2, 8-oxo-diazacyclononane derivative and its synthesis process and application | 广西师范大学 | 2021-05-11 | — | — | CN | disclosed |
| CN-108623530-B | 1,2, 8-oxo-diazacyclononane-9-thioketone derivative and synthetic method and application thereof | 广西师范大学 | 2021-05-11 | — | — | CN | disclosed |
| CN-108727293-B | 1,2, 8-oxo diazacyclononane-9-one derivative and synthetic method thereof | 广西师范大学 | 2021-05-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708337-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | NDC1, SDC1, SDC2 | CRBN 2147/4885FKBP5 1111/4885OR51E2 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.